22:27 , Jul 16, 2018 |  BC Extra  |  Financial News

Malin appoints Curley as chairman

Life sciences investing company Malin Corp. plc (ISE:MLC) appointed Ian Curley as chairman. He was CEO at packaging company Ardagh Group S.A. (NYSE:ARD). Malin provides capital and operational expertise to small life science businesses. Its portfolio...
00:59 , Jun 30, 2018 |  BioCentury  |  Regulation

Not a test

Antibiotics developers shouldn’t read too much into FDA’s rejection of the first drug to be reviewed under a new limited-use pathway that is supposed to make it easier to develop treatments for rare and resistant...
15:03 , Jun 29, 2018 |  BC Week In Review  |  Clinical News

FDA approves plazomicin for cUTI, but not blood infections

Achaogen Inc. (NASDAQ:AKAO) said FDA approved Zemdri plazomicin to treat complicated urinary tract infections (cUTIs), but issued a complete response letter for the same candidate to treat bloodstream infections. The mixed decision is in line...
15:30 , Jun 26, 2018 |  BC Extra  |  Company News

FDA approves plazomicin for cUTI, but not blood infections

Achaogen Inc. (NASDAQ:AKAO) said FDA approved Zemdri plazomicin to treat complicated urinary tract infections (cUTIs), but issued a complete response letter for the same candidate to treat bloodstream infections. The mixed decision is in line...
19:13 , Jun 1, 2018 |  BC Week In Review  |  Financial News

Melinta closes $123.2M follow-on

Anti-infectives company Melinta Therapeutics Inc. (NASDAQ:MLNT) raised $123.2 million through the sale of 24.6 million shares at $5 in a follow-on underwritten by J.P. Morgan, Jefferies and Cantor Fitzgerald. The figures include the sale of...
17:14 , May 24, 2018 |  BC Extra  |  Financial News

Melinta raises $110M in follow-on

Anti-infectives company Melinta Therapeutics Inc. (NASDAQ:MLNT) raised $110 million through the sale of 22 million shares at $5 in a follow-on underwritten by J.P. Morgan, Jefferies and Cantor Fitzgerald. The price is a 32% discount...
01:16 , Mar 30, 2018 |  BC Innovations  |  Finance

Bug money

Despite the tremendous public health need and the introduction of regulatory incentives including expedited review and market exclusivity, venture investing in antibiotics remains modest and focused primarily on clinical assets seeking to improve on known...
00:45 , Mar 2, 2018 |  BC Extra  |  Company News

Medicines Co. board could tilt toward Denner’s control

The Medicines Co. (NASDAQ:MDCO) said it plans to reduce its board members to seven from 12, according to an SEC filing, with many of the directors it plans to nominate at its annual meeting affiliated...
00:38 , Jan 31, 2018 |  BC Extra  |  Company News

Management tracks: Ipsen, Dragonfly

Ipsen Group (Euronext:IPN; Pink:IPSEY) appointed Sotirios Stergiopoulos CMO. He will continue to serve as SVP, head of global medical affairs. Cancer company Dragonfly Therapeutics Inc. (Cambridge, Mass.) hired Jean-Marie Cuillerot as CMO. He was CMO at...
00:38 , Jan 6, 2018 |  BioCentury  |  Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to a...